Devonian Health Group Inc. (TSXV:GSD)
Canada · Delayed Price · Currency is CAD 8.63
0.00 (0.00%)
Sep 17, 2026, 4:10 PM EST
Devonian Health Group Revenue
Devonian Health Group had revenue of 176.64K CAD in the quarter ending April 30, 2026, a decrease of -97.60%. This brings the company's revenue in the last twelve months to 3.00M, down -90.48% year-over-year. In the fiscal year ending July 31, 2025, Devonian Health Group had annual revenue of 23.59M with 22.19% growth.
Revenue (ttm)
3.00M
Revenue Growth
-90.48%
P/S Ratio
8.01
Revenue / Employee
299.53K
Employees
11
Market Cap
23.98M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jul 31, 2025 | 23.59M | 4.28M | 22.19% |
| Jul 31, 2024 | 19.31M | 16.96M | 723.15% |
| Jul 31, 2023 | 2.35M | 40.20K | 1.74% |
| Jul 31, 2022 | 2.31M | 830.50K | 56.32% |
| Jul 31, 2021 | 1.47M | -668.47K | -31.19% |
| Jul 31, 2020 | 2.14M | -1.86M | -46.49% |
| Jul 31, 2019 | 4.00M | 837.05K | 26.42% |
| Jul 31, 2018 | 3.17M | - | - |
| Jul 31, 2017 | - | - | - |
| Jul 31, 2016 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Telescope Innovations | 7.30M |
| Pharmala Biotech Holdings | 1.27M |
| Onco-Innovations | 90.88K |
| The More Life Company | 70.00K |
| Alzai Health | 27.04K |
Devonian Health Group News
- 8 days ago - Devonian Health Group Inc. Anticipates to Commence Trading on the NYSE American - PRNewsWire
- 18 days ago - Devonian Health Group Strengthens Thykamine™ Manufacturing Platform with Validated Chemical-Composition Fingerprinting and Biological Potency Assay - PRNewsWire
- 4 weeks ago - Devonian Health Group Anticipates to Commence Trading on the NYSE American - PRNewsWire
- 7 weeks ago - Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering - PRNewsWire
- 2 months ago - Devonian Health Group Receives Health Canada Authorization to Initiate Phase II/III Pediatric Clinical Trial of Thykamine™ for Mild-to-Moderate Atopic Dermatitis in Patients Aged 3 Months to 17 Years - PRNewsWire
- 2 months ago - Devonian Health Group Reports Financial and Operating Results of its Three and Nine Months Ended April 30, 2026 - PRNewsWire
- 5 months ago - Devonian Reports Results of its Annual General and Special Meeting of Shareholders - PRNewsWire
- 5 months ago - Devonian Health Group Inc. Reports Financial and Operating Results of its Three and Six Months Ended January 31, 2026 - PRNewsWire